Lysophosphatidylcholine--biomarker of Metformin action: studied using UPLC/MS/MS.
An UPLC/MS/MS based metabonomic method was developed and applied to the elucidation of biomarker of metformin action. The plasma metabolite profiling in healthy volunteers before and after per os metformin was determined with UPLC/MS/MS and analyzed by using multivariate statistics. Significant difference in endogenous metabolite profiles was revealed before and after administration of metformin. Four biomarkers found were lysophosphatidylcholines (LPCs), and their structures were tentatively identified to be 16:0 LPC, 18:0 LPC, 18:1 LPC and 18:2 LPC according to the molecular ions information and corresponding fragments of product ion scan. Lysophosphatidylcholine in blood may be involved in metformin treatment.
Cai
Shuang
S
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
Huo
Taoguang
T
Li
Ning
N
Xiong
Zhili
Z
Li
Famei
F
D000328:Adult; D015415:Biomarkers / Q000097:blood* / Q000737:chemistry / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D008244:Lysophosphatidylcholines / Q000097:blood* / Q000737:chemistry / Q000378:metabolism; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000378:metabolism*; D015999:Multivariate Analysis; D025341:Principal Component Analysis; D053719:Tandem Mass Spectrometry / Q000379:methods*
D015415:Biomarkers; D008244:Lysophosphatidylcholines; D008687:Metformin